All In Biotech

Drug Trial Radar · NCT05275855

First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

A First-in-human, Randomized, Participant and Investigator Blinded, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Apr 29, 2022

Primary completion

Dec 18, 2024

Study completion Dec 18, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of EDI048 administered orally in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • EDI048Drug

    Oral Liquid

  • PlaceboOther

    Oral Liquid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 8.5 weeks for Part A and 9 weeks for Part B

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Mere Way, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.